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In utero mammalian development relies on the establishment of
the maternal–fetal exchange interface, which ensures transporta-
tion of nutrients and gases between the mother and the fetus.
This exchange interface is established via development of multi-
nucleated syncytiotrophoblast cells (SynTs) during placentation. In
mice, SynTs develop via differentiation of the trophoblast stem
cell-like progenitor cells (TSPCs) of the placenta primordium, and
in humans, SynTs are developed via differentiation of villous cyto-
trophoblast (CTB) progenitors. Despite the critical need in preg-
nancy progression, conserved signaling mechanisms that ensure
SynT development are poorly understood. Herein, we show that
atypical protein kinase C iota (PKCλ/ι) plays an essential role in
establishing the SynT differentiation program in trophoblast pro-
genitors. Loss of PKCλ/ι in the mouse TSPCs abrogates SynT devel-
opment, leading to embryonic death at approximately embryonic day
9.0 (E9.0). We also show that PKCλ/ι-mediated priming of trophoblast
progenitors for SynT differentiation is a conserved event during hu-
man placentation. PKCλ/ι is selectively expressed in the first-trimester
CTBs of a developing human placenta. Furthermore, loss of PKCλ/ι in
CTB-derived human trophoblast stem cells (human TSCs) impairs their
SynT differentiation potential both in vitro and after transplantation
in immunocompromised mice. Our mechanistic analyses indicate that
PKCλ/ι signaling maintains expression of GCM1, GATA2, and PPARγ,
which are key transcription factors to instigate SynT differentiation
programs in both mouse and human trophoblast progenitors. Our
study uncovers a conserved molecular mechanism, in which PKCλ/ι
signaling regulates establishment of thematernal–fetal exchange sur-
face by promoting trophoblast progenitor-to-SynT transition during
placentation.
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Trophoblast progenitors are critical for embryo implantationand early placentation. Defective development and differ-
entiation of trophoblast progenitors during early human pregnancy
either leads to pregnancy failure (1–4), or pregnancy-associated
complications like fetal growth restriction and preeclampsia (3–6),
or serves as the developmental cause for postnatal or adult diseases
(7–9). However, due to experimental and ethical barriers, we have a
poor understanding of molecular mechanisms that are associated
with early stages of human placentation. Rather, gene knockout
(KO) studies in mice have provided important information about
molecular mechanisms that regulate mammalian placentation.
While mouse and human placentae differ in their morphology and
trophoblast cell types, important similarities exist in the formation
of the maternal–fetal exchange interface. Both mice and humans
display hemochorial placentation (10), where the maternal–fetal
exchange interface is established via direct contact between ma-
ternal blood and placental syncytiotrophoblast cells (SynTs).
In a periimplantation mouse embryo, proliferation and dif-
ferentiation of polar trophectoderm results in the formation of
trophoblast stem cell-like progenitor cells (TSPCs), which reside
within the extraembryonic ectoderm ExE (11), and later in ExE-
derived ectoplacental cone (EPC) and chorion. Subsequently,
the TSPCs within the ExE/EPC region contribute to develop the
junctional zone, a compact layer of cells sandwiched between the
labyrinth and the outer trophoblast giant cell (TGC) layer. De-
velopment of the junctional zone is associated with differentia-
tion of trophoblast progenitors to four trophoblast cell lineages:
1) TGCs (12), 2) spongiotrophoblast cells (13), 3) glycogen cells,
and 4) invasive trophoblast cells that invade the uterine wall and
maternal vessels (14–16).
The mouse placental labyrinth, which constitutes the maternal–
fetal exchange interface, develops after the allantois attaches with
the chorion. The multilayered chorion forms around embryonic day
8.0 (E8.0) when chorionic ectoderm fuses to basal EPC, thereby
reuniting TSPC populations separated by formation of the ecto-
placental cavity (17). Subsequently, the chorion attaches with the
allantois to initiate the development of the placental labyrinth,
which contains two layers of SynTs, known as SynT-I and SynT-II. At
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the onset of labyrinth formation, glial cells missing 1 (Gcm1) ex-
pression is induced in the TSPCs of the chorionic ectoderm (18),
which promotes cell cycle exit and differentiation to the SynT-II
lineage (17), whereas the TSPCs of the basal EPC progenitors
that express Distal-less 3 (Dlx3) contribute to syncytial SynT-I
lineage (17).
In contrast to mice, the earliest stage of human placentation is
associated with the formation of a zone of invasive primitive
syncytium at the blastocyst implantation site (19–21). Later,
columns of cytotrophoblast cell (CTB) progenitors penetrate the
primitive syncytium to form primary villi. With the progression of
pregnancy, primary villi eventually branch and mature to form
the villous placenta, containing two types of matured villi: 1)
anchoring villi, which anchor to maternal tissue, and 2) floating
villi, which float in the maternal blood of the intervillous space
(19–21). The proliferating CTBs within anchoring and floating
villi adapt distinct differentiation fates during placentation (22).
In anchoring villi, CTBs establish a column of proliferating CTB
progenitors known as column CTBs (22), which differentiate to
invasive extravillous trophoblasts (EVTs), whereas CTB pro-
genitors of floating villi (villous CTBs) differentiate and fuse to
form the outer multinucleated SynT layer. The villous CTB-
derived SynTs establish the nutrient, gas, and waste exchange
surface, produce hormones, and promote immune tolerance to
fetus throughout gestation (23–28).
Thus, the establishment of the placental exchange surface in
both mice and humans are associated with the formation of
differentiated, multinucleated SynTs from the trophoblast pro-
genitors of placenta primordia. Moreover, both mouse and hu-
man trophoblast progenitors express key transcription factors,
such as GCM1, DLX3, peroxisome proliferator-activated nu-
clear receptor gamma (PPARγ), and GATA binding protein 2
(GATA2), which have been shown to be important for SynT
development during placentation (1–4, 29–33). Despite these
similarities, conserved signaling pathways that program SynT
development in both mouse and human trophoblast progenitors
are incompletely understood. Fortunately, the success in deriving
true human trophoblast stem cells (TSCs) from villous CTBs
(34) have opened up possibilities for direct assessment of con-
served mechanisms that prime differentiation of multipotent
trophoblast progenitor to SynT lineage. Therefore, we herein
analyzed both mouse mutants and human TSCs to test the spe-
cific role of PKCλ/ι in that process.
The PKCλ/ι belongs to the atypical group of PKCs, which
consists of another isoform PKCζ. The aPKC isoforms have been
implicated in cell lineage patterning in preimplantation embryos
(35). We demonstrated that both PKCζ and PKCλ/ι regulate self-
renewal vs. differentiation potential in both mouse and rat em-
bryonic stem cells (36–38). Interestingly, gene KO studies in
mice indicated that PKCζ is dispensable for embryonic devel-
opment (39), whereas ablation of PKCλ/ι results in early gesta-
tion abnormalities leading to embryonic lethality (40, 41) prior to
E9.5, a developmental stage equivalent to first trimester in hu-
mans. However, the importance of PKCλ/ι in the context of
postimplantation trophoblast lineage development during mouse
or human placentation has never been addressed. We found that
PKCλ/ι protein is specifically abundant in TSPCs and villous
CTBs within the developing mouse and human placenta, re-
spectively. We show that both global and trophoblast-specific
loss of PKCλ/ι in a mouse embryo is associated with defective
development of placental labyrinth due to impairment of gene
expression programming that ensures SynT development. We
further demonstrate that the PKCλ/ι signaling in human TSCs is
also essential for maintaining their SynT differentiation potential.
Our analyses revealed an evolutionarily conserved, developmental-
stage–specific mechanism in which PKCλ/ι-signaling orchestrates
gene expression program in trophoblast progenitors for successful
progression of in utero mammalian development.
Results
PKCλ/ι Protein Expression Is Selectively Abundant in the Trophoblast
Progenitors of Developing Mouse and Human Placentae. Earlier
studies showed that PKCλ/ι is ubiquitously expressed in all cells
of a developing preimplantation mouse embryo (42), including
the trophectoderm cells. Also, another study showed that PKCλ/ι
is ubiquitously expressed in both embryonic and extraembryonic
cell lineages in a postimplantation E7.5 mouse embryo (41). We
validated both of these observations in a blastocyst (SI Appendix,
Fig. S1A) and in E7.5 mouse embryo (SI Appendix, Fig. S1B).
However, relative abundance of PKCλ/ι protein expression in
different cell types is not well documented during postimplantation
mouse development. Therefore, we tested PKCλ/ι protein expres-
sion at different stages of mouse postimplantation development.
We found that in approximately E8 mouse embryos, PKCλ/ι protein
is most abundantly expressed in the TSPCs residing in the placenta
primordium (Fig. 1A). In comparison, cells within the developing
embryo proper showed very low levels of PKCλ/ι protein expression.
The high abundance of PrkcimRNA and PKCλ/ι protein expression
was detected in the trophoblast cells of an E9.5 mouse embryo (SI
Appendix, Fig. S1C and Fig. 1B). We also observed that PKCλ/ι is
expressed in the maternal decidua. Surprisingly, the embryo proper
showed extremely low PKCλ/ι protein expression at this de-
velopmental stage. The abundance of PKCλ/ι protein expression in
the trophoblast is also maintained as development progresses.
However, cells in the embryo proper also show PKCλ/ι protein
expression beginning at midgestation as in E12.5 (SI Appendix,
Fig. S1D).
As PKCλ/ι expression during human placentation has never
been tested, we investigated PKCλ/ι protein expression in human
placentae at different stages of gestation. Our analyses revealed
that PKCλ/ι protein is expressed specifically in the villous CTBs
within a first-trimester human placenta (Fig. 1C). PKCλ/ι is also
expressed in CTBs within term placenta (Fig. 1C). To further
quantitate PKCλ/ι expression, we isolated CTBs from first-
trimester and term placentae and analyzed PRKCI mRNA ex-
pression. We also isolated SynT from term placentae via laser
capture microdissection (SI Appendix, Fig. S1E). We found that
PRKCI mRNA expression is approximately twofold higher in
first-trimester CTBs compared to that in term CTBs (SI Appendix,
Fig. S1F). However, PKCλ/ι expression is strongly repressed in
differentiated SynTs in first-trimester human placentae (Fig. 1C) as
well as in term placentae (SI Appendix, Fig. S1F).
Global Loss of PKCλ/ι in a Developing Mouse Embryo Abrogates
Placentation. Global deletion of Prkci in a developing mouse
embryo (PKCλ/ι KO embryo) results in gastrulation defect
leading to embryonic lethality (40, 41) at approximately E9.5.
However, the placentation process was never studied in PKCλ/ι
KO mouse embryos. As many embryonic lethal mouse mutants
are associated with placentation defects, we probed into tro-
phoblast development and placentation in postimplantation
PKCλ/ι KO embryos. We started investigating placenta and
trophoblast development in PKCλ/ι KO embryos starting from
E7.5. At this stage, the placenta primordium consists of the ExE/
EPC regions. However, we did not notice any obvious pheno-
typic differences of the ExE/EPC development between the
control and the PKCλ/ι KO embryos at E7.5 (Fig. 2 A, Left, and
SI Appendix, Fig. S2A). We noticed developmental defect in
PKCλ/ι KO placentae after the chorio-allantoic attachment, an
event which takes place at approximately E8.5. We noticed that
PKCλ/ι KO developing placentae were smaller in size at E8.5
(Fig. 2 A, Middle), and this defect in placentation was more
prominent in E9.5 embryos. At E9.5, the placentae in PKCλ/ι
KO embryos were significantly smaller in size (Fig. 2 A, Right,
and SI Appendix, Figs. S2A and S3A), and the embryo proper also
showed gross impairment in development and was significantly









































smaller in size (Fig. 2B and SI Appendix, Figs. S2A and S3A), as
reported in earlier studies (40). Immunofluorescence analyses
revealed defective embryonic–extraembryonic attachment with
an altered orientation of the embryo proper with respect to the
developing placenta (Fig. 2C).
We also failed to detect any visible labyrinth zone in most of
the PKCλ/ι KO placentae. The abrogation of the placental
labyrinth and the SynT development were confirmed by a near-
complete absence of Gcm1 mRNA expression (SI Appendix, Fig.
S2B) and lack of any Dlx3-expressing labyrinth trophoblast cells
in E9.5 PKCλ/ι KO placentae (Fig. 2D). In contrast, the PKCλ/ι
KO placentae mainly contained proliferin (PLF)-expressing
TGCs (SI Appendix, Fig. S3A).
In a very few PKCλ/ι KO placentae (3 out of 32 analyzed by
sectioning), other trophoblast cells exist along with TGCs (SI
Appendix, Fig. S3A, red border). We tested the presence of dif-
ferent trophoblast subtypes in those placentae. We detected
trophoblast-specific protein alpha (Tpbpa)-expressing spongio-
trophoblast population (SI Appendix, Fig. S3B). We also tested
for SynT markers. In a mouse placenta the matured labyrinth
contains two layers of SynTs, SynT-I and SynT-II. The SynT-I
cells express the retroviral gene syncytin A (SynA) (43), whereas
the SynT-II population arises from GCM1-expressing progeni-
tors (17). So, we tested presence of those cells via in situ hy-
bridization. We detected the presence of some SynA-expressing
cells (SI Appendix, Fig. S3B). However, we could not detect any
Gcm1-expressing cells in any of the PKCλ/ι KO placenta (SI
Appendix, Fig. S3B). We further tested formation of SynT-I and
SynT-II layers by analyzing expressions of solute carrier family 16
member 1 (MCT1) and solute carrier family 16 member 3
(MCT4), respectively (44). In contrast to control placentae, in
which we detected development of two MCT1 and MCT4-
expressing SynT layers (SI Appendix, Fig. S3C), we only de-
tected a few MCT1-expressing cells in PKCλ/ι KO placentae.
However, those cells were dispersed, indicating lack of cell fusion
and formation of a matured SynT-I layer. We could not detect
any MCT4-expressing SynT-II cells in PKCλ/ι KO placentae.
These results indicated that loss of PKCλ/ι leads to abrogation of
SynT-II development. Although a few SynA/MCT1-expressing
SynT-I–like populations could arise in a few PKCλ/ι KO pla-
centae, they do not differentiate to a matured SynT-I layer.
We could not test placentation in the PKCλ/ι KO embryos
beyond E9.5 as these embryos and placentae begin to resorb at
late gestational stages. Thus, from our findings, we concluded
that the global loss of PKCλ/ι in a developing mouse embryo
leads to defective placentation after the chorio-allantoic at-
tachment due to impaired development of the SynT lineage,
resulting in abrogation of placental labyrinth formation.
Trophoblast-Specific PKCλ/ι Depletion Impairs Mouse Placentation
Leading to Embryonic Death. Since we observed placentation de-
fect in the global PKCλ/ι KO embryos, we next interrogated the
importance of trophoblast cell-specific PKCλ/ι function in mouse
placentation and embryonic development. Although a Prkci-
conditional KO mouse model exists, we could not get access to
that mouse. Therefore, we performed RNA interference (RNAi)
using lentiviral-mediated gene delivery approach as described
earlier (45) to specifically deplete PKCλ/ι in the developing
trophoblast cell lineage. We transduced zona-removed mouse
blastocysts with lentiviral particles with short hairpin RNA
(shRNA) against Prkci (Fig. 3A) and transferred them to pseu-
dopregnant females. We confirmed the efficiency of shRNA-
mediated PKCλ/ι depletion by measuring Prkci mRNA expres-
sion in transduced blastocysts (Fig. 3B) and also by testing loss of
PKCλ/ι protein expressions in trophoblast cells of developing
placentae in multiple experiments (SI Appendix, Fig. S4 A and
B). Intriguingly, the trophoblast-specific PKCλ/ι depletion also
resulted in embryonic death before E9.5 due to severe defect in
both placental and embryonic development (Fig. 3 C and D).
Furthermore, the immunofluorescence analyses of trophoblast
cells at approximately E9.5 confirmed defective placentation
in the Prkci knockdown (KD) placentae, characterized with a
near-complete absence of the labyrinth zone (Fig. 3E) and
Dlx3-expressing SynT populations (Fig. 3F). However, similar
to PKCλ/ι KO placentae, Prkci KD placentae predominantly
Fig. 1. PKCλ/ι protein expression is selectively abundant in trophoblast
progenitors of early postimplantation mammalian embryos. (A) Immuno-
fluorescence images showing trophoblast progenitors, marked by anti-
pancytokeratin antibody (green), expressing high levels of PKCλ/ι protein
(red) in an approximately E8 mouse embryo. Note much less expression of
PKCλ/ι protein within cells of the developing embryo proper (orange dotted
boundary). EPC, chorion, allantois, and the chorio-allantoic attachment site
are indicated with yellow, white, and pink dotted lines, and a white asterisk,
respectively. (Scale bars, 100 μm.) (B) Immunofluorescence images of an E9.5
mouse implantation sites showing pan-cytokeratin (Left), PKCλ/ι (Right), and
nuclei (DAPI). At this developmental stage, PKCλ/ι protein is highly expressed
in trophoblast cells of the developing placenta and in maternal uterine cells.
However, PKCλ/ι protein expression is much less in the developing embryo.
(Scale bars, 500 μm.) (C) Immunohistochemistry showing PKCλ/ι is selectively
expressed within the cytotrophoblast progenitors (green arrows) of first-
trimester (8 wk) and term (38 wk) human placentae. (Scale bars, 50 μm.)




























contained PLF-expressing TGC populations (SI Appendix,
Fig. S4C). Thus, the trophoblast-specific depletion of PKCλ/ι
in a developing mouse embryo recapitulated similar placentation
defect and embryonic death as observed in the global PKCλ/ι KO
embryos.
PKCλ/ι Signaling in a Developing Mouse Embryo Is Essential to Establish a
Transcriptional Program for TSPC-to-SynT Differentiation. The abroga-
tion of labyrinth development in the trophoblast-specific Prkci KD
mouse placentae indicated a critical importance of the PKCλ/ι
signaling in SynT development and labyrinth formation. During
mouse placentation, the SynT differentiation is associated with the
suppression of TSC/TSPC-specific genes, such as caudal-type ho-
meobox 2 (Cdx2), Eomesodermin (Eomes), TEA domain transcription
factor 4 (Tead4), estrogen-related receptor beta (Esrrβ), and E74-like
transcription factor 5 (Elf5) (2, 46–50), and induction of expression of
the SynT-specific genes, such as Gcm1, Dlx3, and fusogenic retroviral
genes SyncytinA and SyncytinB (3). In addition, other transcription
factors, such as PPARγ, GATA transcription factors GATA2 and
GATA3, and cell signaling regulators, including members of mitogen-
activated protein kinase pathway, are implicated in mouse SynT devel-
opment (32, 33, 51). Therefore, to define the molecular mechanisms of
PKCλ/ι-mediated regulation of SynT development, we specifically de-
pleted PKCλ/ι expression in mouse TSCs via RNAi (Fig. 4A) and asked
whether the loss of PKCλ/ι impairs mouse TSC self-renewal or their
differentiation to specialized trophoblast cell types.
When cultured in stem state culture condition (with FGF4 and
heparin), PKCλ/ι-depleted mouse TSCs (Prkci KD mouse TSCs)
did not show any defect in the stem state colony morphology
(Fig. 4B). Also, cell proliferation analyses by MTT assay and
Fig. 2. Global Loss of PKCλ/ι in a developing mouse embryo abrogates placentation. (A) Experimental strategy and phenotype of mouse conceptuses de-
fining the importance of PKCλ/ι in placentation. Heterozygous (Prkci+/−) male and female mice were crossed to generate homozygous KO (Prkci−/−, PKCλ/ι KO)
embryos and confirmed by genotyping. Embryonic and placental developments were analyzed at E7.5, E8.5, and E9.5, and representative images are shown.
At E7.5, placenta primordium developed normally in PKCλ/ι KO embryos. However, defect in placentation in PKCλ/ι KO conceptuses was observable (smaller
placentae) at E8.5 and was prominent at E9.5. (Scale bars, 100 μm.) (B) Developing control and PKCλ/ι KO embryos were isolated at approximately E9.5, and
representative images are shown. The PKCλ/ι KO embryo proper shows gastrulation defect as described in an earlier study (40). (Scale bars, 500 μm.) (C)
Placentation at control and PKCλ/ι KO implantation sites were analyzed at approximately E9.5 via immunostaining with anti–pan-cytokeratin antibody
(green, trophoblast marker). The developing PKCλ/ι KO placenta lacks the labyrinth zone and mainly contains the TGCs (red line). Also, unlike in control
embryos, the developmentally arrested PKCλ/ι KO placenta and embryo proper are not segregated and are attached together. (Scale bars, 500 μm.) (D) RNA
in situ hybridization assay was performed using fluorescent probes against Dlx3 mRNA. Images show that, unlike the control placenta, the PKCλ/ι KO placenta
lacks Dlx3-expressing labyrinth trophoblast cells. (Scale bars, 500 μm.)









































bromodeoxyuridine (BrdU) incorporation assay indicated that
cell proliferation was not affected in the Prkci KD mouse TSCs
(Fig. 4 C and D). Furthermore, mRNA expression analyses
showed that expression of TSC stem state regulators, such as
Cdx2, Eomes, Gata3, Tead4, Esrrb, and Elf5 were not affected
upon PKCλ/ι depletion (Fig. 4E). Western blot analysis also
confirmed that CDX2 protein expression was not affected in the
Prkci KD TSCs (Fig. 4F). These results indicated that PKCλ/ι
signaling is not essential to maintain the self-renewal program in
mouse TSCs.
Next, we asked whether the loss of PKCλ/ι affects mouse TSC
differentiation program. Removal of FGF4 and heparin from
the culture medium induces spontaneous differentiation in
mouse TSCs, which can be monitored over a course of 6 to 8 d.
During this differentiation program, induction of SynT-
differentiation markers like Gcm1, Dlx3 can be monitored in
Fig. 3. Trophoblast-specific PKCλ/ι depletion impairs mouse placentation leading to embryonic death. (A) Schematics to study developing mouse embryos
with trophoblast-specific depletion of Prkci (Prkci KD embryos). Blastocysts were transduced with lentiviral vectors expressing shRNA against Prkci, and
transduction was confirmed by monitoring EGFP expression. Transduced blastocysts were transferred into the uterine horns of pseudopregnant females to
study subsequent effect on embryonic and placental development. (B) KD efficiency with shRNA was confirmed by testing loss of Prkci mRNA expression in
transduced blastocysts. (C and D) Representative images show control and Prkci KD placentae and developing embryos, isolated at E9.5. Similar to global
PKCλ/ι KO embryos, trophoblast-specific Prkci KD embryos showed severe developmental defect. (E) Immunostaining with anti–pan-cytokeratin antibody
(green, trophoblast marker) showed defective placentation in the Prkci KD implantation sites at approximately E9.5. The images show that, unlike the control
placenta, labyrinth formation was abrogated in the Prkci KD placenta. (Scale bars, 500 μm.) (F) RNA in situ hybridization assay confirmed near-complete
absence of Dlx3-expressing trophoblast cells in the Prkci KD placenta. (Scale bars, 500 μm.)




























differentiating cells between day 2 and day 4. Subsequently,
the TSC markers are repressed in the differentiating TSCs as
the TGC-specific differentiation program becomes more
prominent. Thus, after day 6 of differentiation, mouse TSCs
highly express TGC specific markers, like prolactin family 3
subfamily d member 1 (Prl3d1), heart and neural crest-derived
transcript 1 (Hand1), and prolactin family 2 subfamily c
member 2 (Prl2c2). In addition, trophoblast-specific protein
alpha (Tpbpa), Achaete-scute homolog 2 (Ascl2), Connexin 31
(Cx31), which are markers of spongiotrophoblast and glycogen
trophoblast cells of the placental junctional zone, are also
induced in differentiated mouse TSCs.
As the loss of PKCλ/ι affects labyrinth development, we
monitored expressions of Gcm1 and Dlx3 in differentiating Prkci
KD mouse TSCs. Similar to our findings with the PKCλ/ι-de-
pleted placentae, induction of Dlx3 andGcm1 mRNA expression
was impaired in differentiating Prkci KD mouse TSCs (Fig. 4G).
In contrast, induction of Tpbpa, Prl3d1, and Cx31, which are
markers for spongiotrophoblasts, TGCs, and glycogen cells, re-
spectively, were not affected in differentiated Prkci KD mouse
TSCs (Fig. 4H). Thus, we concluded that the loss of PKCλ/ι in
mouse TSCs does not affect their differentiation to specialized
trophoblast cells of the placental junctional zone, such as spon-
giotrophoblasts, TGCs, and the glycogen cells. Rather, PKCλ/ι is
Fig. 4. PKCλ/ι signaling is essential to establish a transcriptional program for SynT differentiation. (A) Quantitative RT-PCR to validate loss of Prkci mRNA
expression in Prkci KD mouse TSCs (mean ± SE; n = 4, P ≤ 0.001). The shRNA molecules targeting the Prkci mRNA had no effect on Prkcz mRNA expression. (B)
Morphology of control and Prkci KD mouse TSCs. (C and D) Assessing proliferation rate of control and Prkci KD mouse TSCs by MTT assay and BrdU labeling,
respectively. (E) Quantitative RT-PCR (mean ± SE; n = 3), showing unaltered mRNA expression of trophoblast stem state-specific genes like Cdx2, Eomes,
Tead4, Gata3, Elf5, and Esrrb in Prkci KD mouse TSCs. (F) Western blot analyses confirming unaltered CDX2 protein expression in mouse TSCs upon PKCλ/ι
depletion. (G) Prkci KD mouse TSCs were allowed to grow under differentiation conditions, and gene expression analyses of SynT markers Gcm1 and Dlx3
were done (mean ± SE; n = 3). The plots show that loss of PKCλ/ι in mouse TSCs results in impaired induction of Gcm1 and Dlx3 expression. (H) Quantitative RT-
PCR analyses of Prl3d1, Ascl2, Tpbpa, and Cx31mRNA expression in differentiated Prkci KD mouse TSCs (mean ± SE; n = 3) to assess TGCs, spongiotrophoblasts,
and glycogen trophoblast cell differentiation, respectively. Expression of these genes was not altered in differentiated Prkci KD mouse TSCs, indicating PKCλ/ι
is dispensable for mouse TSC differentiation to TGCs, spongiotrophoblasts, and glycogen trophoblast cells.









































essential to specifically establish the SynT differentiation pro-
gram in mouse TSCs.
Based on our findings with Prkci KD mouse TSCs, we hy-
pothesized that the PKCλ/ι signaling might regulate key genes,
which are specifically required to induce the SynT differentiation
program in TSCs. To test this hypothesis, we performed un-
biased whole RNA-sequencing (RNA-seq) analysis with Prkci
KD mouse TSCs. RNA-seq analyses showed that the depletion
of PKCλ/ι in mouse TSCs altered expression of 164 genes by at
least twofold with a high significance level (P ≤ 0.01). Among
these 164 genes, 120 genes were down-regulated and 44 genes
were up-regulated (Fig. 5A and Datasets S1 and S2). Ingenuity
pathway analyses revealed multimodal biofunctions of PKCλ/
ι-regulated genes, including involvement in embryonic and re-
productive developments (Fig. 5B). To further gain confidence
on PKCλ/ι-regulated genes in the mouse TSCs, we curated the
number of altered genes with a false-discovery rate (FDR)
threshold of 0.1. The FDR filtering identified only 6 up-
regulated genes and 46 down-regulated genes in the Prkci KD
mouse TSCs (Fig. 5 C and D and Dataset S3). Among the down-
regulated genes, Prkci was identified as the most significantly
altered gene, thereby confirming the specificity and high effi-
ciency of the shRNA-mediated Prkci depletion.
Among the six genes, which were significantly up-regulated in
Prkci KD mouse TSCs, only growth differentiation factor 6
(Gdf6) has been implicated in trophoblast biology in an over-
expression experiment with embryonic stem cells (52). However,
Gdf6 deletion in a mouse embryo does not affect placentation
(53, 54). In contrast, three transcription factors, Gata2, Pparg,
and Cited2, which were significantly down-regulated in the Prkci
KD mouse TSCs, are implicated in the regulation of trophoblast
differentiation and labyrinth development. Earlier gene KO
studies implicated CITED2 in the placental labyrinth formation.
However, CITED2 is proposed to have a non–cell-autonomous
role in SynT as its function is more important in proper pat-
terning of embryonic capillaries in the labyrinth zone rather than
in promoting the SynT differentiation (55). In contrast, KO
studies in mouse TSCs indicated that PPARγ is an important
regulator for SynT differentiation (32). PPARγ-null mouse TSCs
showed specific defects in SynT differentiation and rescue of
PPARγ expression rescued Gcm1 expression and SynT differ-
entiation. Also, earlier, we showed that in mouse TSCs, GATA2
directly regulates expression of several SynT-associated genes
including Gcm1 and, in coordination with GATA3, ensures
placental labyrinth development (33). Therefore, we focused our
study on GATA2 and PPARγ and further tested their expres-
sions in Prkci KD mouse TSCs and PKCλ/ι KO placenta pri-
mordium. We validated the loss of GATA2 and PPARγ protein
expressions in Prkci KD mouse TSCs (Fig. 5E). Our analyses
confirmed that both Gata2 and Pparg mRNA expression are
significantly down-regulated in E7.5 PKCλ/ι KO placenta pri-
mordium (Fig. 5F) and the loss of Gata2 and Pparg expression
was subsequently associated with impaired transcriptional in-
duction of both Gcm1 and Dlx3 in E8.5 PKCλ/ι KO placentae
(Fig. 5G). Thus, our studies in Prkci KDmouse TSCs and PKCλ/ι
KO placenta primordium indicated a regulatory pathway, in
which the PKCλ/ι signaling in differentiating TSPCs ensures
GATA2 and PPARγ expression, which in turn establishes proper
transcriptional program for SynT differentiation (Fig. 5H).
PKCλ/ι Is Critical for Human Trophoblast Progenitors to Undergo
Differentiation toward SynT Lineage. Our expression analyses
revealed that PKCλ/ι expression is conserved in CTB progenitors
of a first-trimester human placenta. However, functional im-
portance of PKCλ/ι in the context of human trophoblast devel-
opment and function has never been tested. We wanted to test
whether PKCλ/ι signaling mediates a conserved function in hu-
man CTB progenitors to induce SynT differentiation. However,
testing molecular mechanisms in isolated primary first-trimester
CTBs is challenging due to lack of established culture conditions,
which could maintain CTBs in a self-renewing stage or could
promote their differentiation to SynT lineage. Rather, the recent
success of derivation of human TSCs from first-trimester CTBs
(34) has opened up opportunities to define molecular mecha-
nisms that control human trophoblast lineage development.
When grown in media containing a Wnt activator CHIR99021,
EGF, Y27632 (a Rho-associated protein kinase [ROCK] in-
hibitor), A83-01 and SB431542 (TGF-β inhibitors), and valproic
acid (a histone deacetylase [HDAC] inhibitor), the established
human TSCs can be maintained in a self-renewing stem state for
multiple passages. In contrast, when cultured in the presence of
cAMP agonist forskolin, human TSCs synchronously differenti-
ate and fuse to form two-dimensional (2D) syncytia on a high-
attachment culture plate or 3D cyst-like structures on a low-
adhesion culture plate. In both 2D and 3D culture conditions,
differentiated human TSCs highly express SynT markers and
secrete a large amount of human CG (hCG). Thus, depending
on the culture conditions, human TSCs efficiently recapitulate
both the self-renewing CTB progenitor state and their differen-
tiation to SynTs. Therefore, we used human TSCs as a model
system and performed loss-of-function analyses to test impor-
tance of PKCλ/ι signaling in human TSC self-renewal vs. their
differentiation toward the SynT lineage.
We performed lentiviral-mediated shRNA delivery to deplete
PKCλ/ι expression in human TSCs (PRKCI KD human TSCs).
The shRNA-mediated RNAi in human TSCs reduced PRKCI
mRNA expression by more than 90% without affecting the
PRKCZ mRNA expression (Fig. 6 A and B), thereby confirming
the specificity of the RNAi approach. Similar to Prkci KD mouse
TSCs, GATA2, PPARG, and GCM1 mRNA expressions were
significantly reduced in PRKCI KD human TSCs (Fig. 6A).
Western blot analyses also confirmed loss of GATA2 and
PPARγ protein expressions in PRKCI KD human TSCs
(Fig. 6B). However, the loss of PKCλ/ι expression in human
TSCs did not overtly affect their stem state morphology (Fig. 6C
and SI Appendix, Fig. S5A), proliferation (SI Appendix, Fig. S5 B
and C), or expression of trophoblast stem state markers, such as
TEAD4 or CDX2 (SI Appendix, Fig. S5D). Rather, we observed a
smaller (∼25%) induction in ELF5 mRNA expression upon loss
of PKCλ/ι (SI Appendix, Fig. S5D). Thus, we concluded that
PKCλ/ι signaling is not essential to maintain the self-renewing
stem state in human TSCs; rather, it is important to maintain
optimum expression of key genes like GATA2, PPARG, and
GCM1, which are known regulators of SynT differentiation.
Therefore, we next interrogated SynT differentiation efficiency
in PRKCI KD human TSCs.
We cultured control and PRKCI KD human TSCs with for-
skolin on both high- and low-adhesion culture plates to test the
efficacy of both 2D and 3D syncytium formation. We assessed
2D SynT differentiation by monitoring elevated mRNA expres-
sions of key SynT-associated genes, such as the HCGβ compo-
nents CGA and CGB; retroviral fusogenic protein ERVW1, and
pregnancy-associated glycoprotein, PSG4. We also tested HCGβ
protein expression and monitored cell syncytialization via loss of
E-CADHERIN (CDH1) expression in fused cells. We found strong
impairment of SynT differentiation of PRKCI KD human TSCs
(Fig. 6 D–F). Unlike in control human TSCs, mRNA induction of
key SynT-associated genes (Fig. 6G) as well as HCGβ protein ex-
pression were strongly inhibited in PRKCI KD human TSCs. Fur-
thermore, PRKCIKD human TSCs maintained strong expression of
CDH1 and showed a near-complete inhibition of cell fusion (Fig. 6E).
The impaired SynT differentiation potential in PRKCI KD
human TSCs were also evident in the 3D culture conditions.
Unlike control human TSCs, which efficiently formed large cyst-
like spheres (larger than 50 μm in diameter), PRKCI KD human
TSCs failed to efficiently develop into larger spheres and mainly




























developed smaller cellular aggregates (Fig. 6 H and I). Also,
comparative mRNA expression analyses indicated more abun-
dance of PRKCI mRNA in a few larger spheres, which were
developed with PRKCI KD human TSCs, indicating that the
large spheres are formed from cells, in which RNAi-mediated
gene depletion was inefficient. We noticed significant inhibition
of CGA, CGB, ERVW1, and PSG4 mRNA inductions in the
small cell aggregates, which also showed significant down-
regulation in PRKCI mRNA expressions (Fig. 6J). We also
confirmed loss of HCG secretion by PRKCI KD human TSCs by
measuring HCG concentration in the culture medium (Fig. 6K).
Thus, both 2D and 3D SynT differentiation systems revealed
impaired SynT differentiation potential of the PRKCI KD
human TSCs.
PKCλ/ι Signaling Is Essential for In Vivo SynT Differentiation Potential
of Human TSCs. As discussed above, our in vitro differentiation
analysis indicated an important role of PKCλ/ι signaling in
inducing SynT differentiation potential in the human TSCs.
However, the in vitro differentiation system lacks the complex
cellular environment and regulatory factors that control SynT
development during placentation. Okae et al. (34) showed
that upon subcutaneous (s.c.) injection into nondiabetic–
severe combined immunodeficiency mice (NOD-SCID mice),
human TSCs invaded the dermal and underlying tissues to
establish trophoblastic lesions. These trophoblastic lesions
contain cells that represent all cell types of a villous human
placenta, namely CTB, SynT, and EVT. Therefore, we next
tested in vivo SynT differentiation potential of PRKCI KD
Fig. 5. PKCλ/ι signaling regulates expression of GATA2 and PPARγ, key transcription factors for SynT differentiation, in mouse TSCs and primary TSPCs of a
mouse placenta primordium. (A) Whole-genome RNA-seq was performed in Prkci KD mouse TSCs, and the Venn diagram shows number of genes that were
significantly down-regulated (120 genes) and up-regulated (44 genes) upon PKCλ/ι depletion. (B) The plot shows most significant biofunctions (identified via
Ingenuity Pathway Analysis) of PKCλ/ι-regulated genes in mouse TSCs. (C and D) Heatmap and volcano plot, respectively, showing significantly altered genes
in Prkci KD mouse TSCs. Along with Prkci, Gata2 and Pparg (marked in red) are among the most significantly down-regulated genes in Prkci KD mouse TSCs.
(E) Western blot analyses showing loss of GATA2 and PPARγ protein expressions in Prkci KD mouse TSCs. (F) Quantitative RT-PCR analyses showing down-
regulation of Gata2 and Pparg mRNA expression in TSPCs of E7.5 PKCλ/ι KO placenta primordium (mean ± SE; n = 4, P ≤ 0.01). Expression of Hand1 and Prkcz
mRNAs remain unaltered. (G) Quantitative RT-PCR analyses in E7.5 and E8.5 PKCλ/ι KO placenta primordia (mean ± SE; n = 4, P ≤ 0.001) showing abrogation of
Gcm1 and Dlx3 induction, which happens between E7.5 and E8.5, in PKCλ/ι KO developing placentae. (H) The model implicates a PKCλ/ι–GATA2/PPARγ–GCM1/
DLX3 regulatory axis in SynT differentiation during mouse placentation.









































human TSCs via transplantation in the NOD-SCID mice
(Fig. 7A). Upon transplantation, both control and PRKCI KD
human TSCs generated tumors with similar efficiency (Fig.
7B), and the presence of human trophoblast cells was con-
firmed via analyses of human KRT7 expression (Fig. 7C).
However, unlike control human TSCs, lesions that were de-
veloped from PRKCI KD human TSCs were largely devoid of
HCGβ-expressing SynT populations (Fig. 7D). We also
confirmed loss of GATA2 and GCM1 mRNA expressions in
lesions that were developed from PRKCI KD human TSCs
(SI Appendix, Fig. S6 A–C). We also tested PPARG mRNA
levels and found relatively lower expression in lesions gen-
erated from PRKCI KD human TSCs. However, the re-
duction level was not statistically significant (SI Appendix,
Fig. S6B). Collectively, our in vitro differentiation and
in vivo transplantation assays with human TSCs imply an es-
sential and conserved molecular mechanism, in which the
PKCλ/ι signaling promotes expression of key transcription
factors, like GATA2, PPARγ, and GCM1, to assure CTB-to-SynT
differentiation.
Fig. 6. Loss of PKCλ/ι impairs SynT differentiation potential in human TSCs. (A) Quantitative RT-PCR analyses showing loss of GATA2, PPARG, and GCM1
mRNA expression (mean ± SE; n = 4, P ≤ 0.01) upon KD of PRKCI in human TSCs (PRKCI KD human TSCs). The mRNA expression of PRKCZ was not affected.
(B) Western blots show loss of PKCλ/ι, GATA2, and PPARγ protein expressions in PRKCI KD human TSCs. (C ) Micrographs showing morphology of control
and PRKCI KD human TSCs. (D and E ) Control and PRKCI KD human TSCs were subjected to two-dimensional (2D) SynT differentiation on collagen-coated
adherent cell culture dishes. Image panels show altered cellular morphology (D); maintenance of E-Cadherin (CDH1) expression (Upper Right in E ); and
impaired induction of HCGβ expression (Lower Right in E ) in PRKCI KD human TSCs. (F ) Cell fusion index was quantitated in control and PRKCI KD human
TSCs. Fusion index was determined by measuring number of fused nuclei with respect to total number of nuclei within image fields (five randomly se-
lected fields from individual experiments were analyzed; three independent experiments were performed). (G) Quantitative RT-PCR analyses showing
significant (mean ± SE; n = 4, P ≤ 0.001) down-regulation of mRNA expressions of SynT-specific markers in PRKCI KD human TSCs, undergoing 2D SynT
differentiation. (H) Control and PRKCI KD human TSCs were subjected to 3D SynT differentiation on low-attachment dishes. Micrographs show defective
SynT differentiation, as assessed from formation of large cell spheres, in PRKCI KD human TSCs. (I) Quantification of 3D SynT differentiation efficiency was
done by counting large cell spheres (>50 μm) from multiple fields (three fields from each experiment; three individual experiments). (J) Quantitative RT-
PCR analyses (mean ± SE; n = 4, P ≤ 0.001) reveal impaired induction of SynT markers in PRKCI KD human TSCs, undergoing 3D SynT differentiation. (K )
The plot shows relative levels of HCG, measured by ELISA with culture medium (mean ± SE; n = 3, P ≤ 0.001) from control and PRKCI KD human TSCs,
undergoing SynT differentiation.





























In this study, using both mouse KO models and human TSCs, we
have uncovered an evolutionarily conserved function of PKCλ/ι
signaling during trophoblast development and mammalian pla-
centation. In recent years, placental development and the
maternal–fetal interaction have been studied with considerable
interest as defects in placentation in early postimplantation embryos
can lead to either pregnancy failure (1–4), or pregnancy-associated
complications like intrauterine growth restriction and preeclampsia
(3–6), or serve as developmental causes for postnatal or adult dis-
eases (7–9). Establishment of the intricate maternal–fetal relation-
ship is instigated by development of the SynT populations, which
not only establish the maternal–fetal exchange surface but also
modulate the immune function and molecular signaling at the
maternal–fetal interface to assure successful pregnancy (56, 57).
Our findings in this study indicate that PKCλ/ι-regulated optimi-
zation of gene expression is fundamental to SynT development.
One of the interesting findings of this study is the specific
requirement of PKCλ/ι in establishing the SynT differentiation
program. The lack of PKCλ/ι expression in SynTs within first
trimester and term human placentae indicates that PKCλ/ι sig-
naling is not required for maintenance of SynT function. The
specific need of PKCλ/ι to “prime” trophoblast progenitors for
SynT differentiation is further evident from the phenotype of
PKCλ/ι-null mouse embryos. Although PKCλ/ι is expressed in
preimplantation embryos and in TSPCs of placenta primordium,
it is not essential for trophoblast cell lineage development at
those early stages of embryonic development. Also, the devel-
opment of TGCs in PKCλ/ι-null placentae indicates that PKCλ/ι
is dispensable for the development of TGCs, a cell type that is
equivalent to human EVTs. Rather, PKCλ/ι is essential for lab-
yrinth development at the onset of chorio-allantoic attachment,
indicating a specific need of PKCλ/ι in nascent SynT population.
Earlier studies with gene KO mice indicated that GCM1 is
essential for the placental labyrinth development. The Gcm1 KO
mice die at E10.5 (58) with major defect in SynT development.
Our findings in this study show that the PKCλ/ι signaling is es-
sential to induce both Gcm1 expression and development of the
SynT-II population. We detected presence of a SynA/MCT1-
expressing, putative SynT-I trophoblast population in a few
PKCλ/ι-KO placentae. However, development of a matured
SynT-I layer was impaired in all PKCλ/ι-KO placentae.
During mouse placentation, Dlx3 is initially induced in basal
EPC progenitors, which constitutes a layer in chorion and
eventually differentiate to SynT-I lineage (17). Later, DLX3 is
broadly expressed in both SynT-I and SynT-II population. Defect
in SynT development and placental labyrinth formation is also
evident in the Dlx3 KO mice by E9.5 (59). We found that both
Gcm1 and Dlx3 transcriptions are induced between E7.5 and
E8.5, a developmental stage when labyrinth development is ini-
tiated upon chorio-allantoic attachment and this induction is
impaired in PKCλ/ι-KO placentae. Not surprisingly, the PKCλ/
ι-KO embryos show a more severe phenotype with complete
absence of matured SynTs in the developing placentae.
Our unbiased gene expression analyses in Prkci KD mouse
TSCs strongly indicate that the PKCλ/ι signaling ensures
TSPC-to-SynT transition by maintaining expression of two con-
served transcription factors, GATA2 and PPARγ. Both GATA2
and PPARγ are known regulators of SynT development. We
showed that Gcm1 and Dlx3 are direct target genes of GATA2 in
mouse TSCs (33). Also, loss of PPARγ in mouse TSCs is asso-
ciated with complete loss of Gcm1 induction during TSC-to-SynT
differentiation (32). Thus, the impairment of Gcm1 and Dlx3 in-
duction upon loss of PKCλ/ι during TSPC-to-SynT transition could
be a direct result of the down-regulation of GATA2 and PPARγ.
In this study, we also found that PKCλ/ι-mediated regulation
of GATA2, PPARγ, and GCM1 is a conserved event in the
mouse and human TSCs. In a recent study (60), we have shown
that GATA2 regulates human SynT differentiation by directly
regulating transcription of key SynT-associated genes, such as
CGA, CGB, and ERVW1, via formation of a multiprotein com-
plex, including histone demethylase KDM1A and RNA poly-
merase II, at their gene loci. Based on the conserved nature of
GATA2 and PPARγ expression and their regulation by PKCλ/ι
in both mouse and human TSCs, we propose that a conserved
PKCλ/ι–GATA2/PPARγ–GCM1 regulatory axis instigates SynT
differentiation during mammalian placentation. We also propose
Fig. 7. PKCλ/ι signaling is essential for in vivo SynT differentiation potential
of human TSCs. (A) Schematics of testing in vivo developmental potential of
human TSC via transplantation assay in NSG mice. Control and PRKCI KD
human TSCs were mixed with Matrigel and were s.c. injected into the flank
of NSG mice. (B) Images show trophoblastic lesions that were developed
from transplanted human TSCs. (Scale bars, 1 cm.) (C and D) Trophoblastic
lesions were immunostained with anti-human cytokeratin7 (KRT7) antibody
and anti-human HCGβ antibody, respectively. The trophoblastic lesions that
were developed from both control and PRKCI KD human TSCs contained
KRT7-expressing human trophoblast cells (C), but the lesions from PRKCI KD
human TSCs lacked HCGβ-expressing trophoblast populations (Right in D),
indicating impairment in SynT developmental potential. (Scale bars, 500 μm.)









































that the PKCλ/ι–GATA2/PPARγ signaling axis mediates the
progenitor-to-SynT differentiation by modulating global transcrip-
tional program, which also involves epigenetic regulators, like
KDM1A. As small molecules could modulate function of most of
the members of this regulatory axis, it will be intriguing to test
whether or not targeting this regulatory axis could be an option to
attenuate SynT differentiation during mammalian placentation.
Another interesting finding of our study is impaired placental
and embryonic development upon loss of PKCλ/ι expression
specifically in trophoblast cell lineage. The trophoblast-specific
PKCλ/ι depletion largely recapitulated the placental and em-
bryonic phenotype of the global PKCλ/ι-KO mice. These results
along with selective abundance of the PKCλ/ι protein expression
in TSPCs of postimplantation mouse embryos indicated that the
defective embryo patterning in global PKCλ/ι-KO mice is prob-
ably an effect of impaired placentation in those embryos. It is
well known that the cells of a gastrulating embryo have signaling
cross talks with the TSPCs of a placenta primordium. Further-
more, defect in placentation is a common phenotype in many
embryonic lethal mouse mutants. However, we have a poor un-
derstanding about how an early defect in labyrinth formation
leads to impairment in embryo patterning, and the specific
phenotype of PKCλ/ι-KO mice provides an opportunity to better
understand this process. Unfortunately, we do not have access to
PKCλ/ι-conditional KO mouse model, and the lentiviral-mediated
shRNA delivery approach did not provide us with an option to
deplete PKCλ/ι in specific trophoblast cell types. During the com-
pletion of this study, we are also establishing a mouse model in
which we will be able to conditionally delete PKCλ/ι in specific
trophoblast cell types to better understand how PKCλ/ι functions in
nascent SynT lineage and how it regulates the cross talk between
the developing embryo proper and the developing placenta. Also,
our finding in this study is an implication of PKCλ/ι signaling in
human trophoblast lineage development and function. As defective
SynT development could be associated with early pregnancy loss or
pregnancy-associated disorders including fetal growth restriction, we
also plan to study whether defective PKCλ/ι function or associated
downstream mechanisms are associated with early pregnancy loss
and pregnancy-associated disorders.
Experimental Procedures
Ethics Statement Regarding Studies with Mouse Model and Human Placental
Tissues. All studies with mouse models were approved by the Institutional
Animal Care and Use Committee at the University of Kansas Medical Center
(KUMC). Human placental tissues (sixth to ninth weeks of gestation) were
obtained from legal pregnancy terminations via the service of Research
Centre for Women’s and Infants’ Health (RCWIH) BioBank at Mount Sinai
Hospital, Toronto, Ontario, Canada. The Institutional Review Boards at the
KUMC and at the Mount Sinai Hospital approved utilization of human pla-
cental tissues and all experimental procedures.
Collection and Analyses of Mouse Embryos. Preimplantation embryos were
isolated at E2.5 and cultured in KSOM to form matured blastocyst. Ten
embryos were used to test for PKCλ/ι expression via immunostaining. Ex-
pressions of PKCλ/ι in postimplantation mouse embryos (from CD1 and Sv/
129 strains) were performed at different developmental stages (E7.5 to
E12.5), and representative images of E7.5, E9.5, and E12.5 are shown in this
manuscript. At least 10 embryos at each developmental stage were used for
the PKCλ/ι expression studies. The Prkci KO mice (B6.129-Prkcitm1Hed/Mmnc)
were obtained from the Mutant Mouse Regional Resource Center, University
of North Carolina. The heterozygous animals were bred to obtain litters and
harvest embryos at different gestational days. Pregnant female animals
were identified by presence of vaginal plug (gestational day 0.5), and em-
bryos were harvested at various gestational days. Uterine horns from
pregnant females were dissected out, and individual embryos were analyzed
under microscope. Tissues for histological analysis were kept in dry-
ice–cooled heptane and stored at −80 °C for cryosectioning. Yolk sacs
from each of the dissected embryos were collected, and genomic DNA
preparation was done using Extract-N-Amp tissue PCR kit (Sigma; XNAT2).
Placenta tissues were collected in RLT buffer, and RNA was extracted using
RNAeasy Mini Kit (Qiagen; 74104). RNA was eluted and concentration was
estimated using Nanodrop ND1000 spectrophotometer. For phenotypic
analyses of PKCλ/ι-KO embryos, we analyzed a total of 101 embryos from 11
litters (SI Appendix, Fig. S2A). For phenotypic analyses of Prkci-KD embryos,
we analyzed 35 control embryos and 36 Prkci-KD embryos from eight indi-
vidual experiments (SI Appendix, Fig. S4A).
Collection and Analyses of Human Placentae. First-trimester placentae were
obtained via services from RCWIH Biobank, Toronto. Normal-term placentae
(≥38 wk of gestation) were collected from cesarean delivery at the KUMC.
For PKCλ/ι expression analyses, eight first-trimester placentae (sixth to ninth
weeks of gestation) were sectioned and immunostained. Additionally, six
normal-term placentae were used for expression analyses.
Human TSC Culture. Human TSC lines, derived from first-trimester CTBs, were
described earlier (34). Although multiple lines were used, the data presented
in this manuscript were generated using CT27 human TSC line. Human TSCs
were cultured in DMEM/F12 supplemented with Hepes and L-glutamine
along with mixture of inhibitors. We followed the established protocol by
T.A.’s group and induced SynT differentiation using forskolin. Both male and
female human TSC lines were used for initial experimentation. To generate
PRKCI KD human TSCs, shRNA-mediated RNAi was performed. For initial
screening, both male and female cell lines were used. As we did not notice
any phenotypic difference after PRKCI depletion, a female PRKCI KD human TSC
line and corresponding control set were used for subsequent experimentation.
Trophectoderm-Specific Prkci KD. Morula from day 2.5 plugged CD-1 super-
ovulated females were treated with acidic Tyrode’s solution for removal of
zona pellucida. The embryos were immediately transferred to EmbryoMax
Advanced KSOM media. Embryos were treated with viral particles having
either control pLKO.3G empty vector or shRNA against Prkci for 5 h. The
embryos were washed two to three times, subsequently incubated overnight
in EmbryoMax Advanced KSOM media, and transferred into day 0.5 pseu-
dopregnant females the following day. Uterine horns of control and KD sets
were harvested at day 9.5. Placental tissue was obtained for RNA prepara-
tion to validate KD efficiency. Embryos were either dissected or kept frozen
for sectioning purpose.
Transplantation of Human TSCs into NSG Mice. For transplantation analyses in
NSG mice, control and PRKCI KD human TSCs were mixed with Matrigel and
used to inject s.c. into the flank of NSG mice (6–9 wk old). A total of 107 cells
was used for each transplantation experiment. Mice were killed after 7 d,
and trophoblastic lesions generated were isolated, photographed, measured
for size, fixed, embedded in paraffin, and sectioned for further analyses.
Three individual experiments were performed, and six mice (three for con-
trol human TSCs and three for PRKCI-KD human TSCs) were used in each
experiment.
Statistical Significance. Statistical significances were determined for quanti-
tative RT-PCR analyses, analyses of SynT-differentiation efficiency and HCG
secretion by human TSCs. We have performed at least n = 3 experimental
replicates for all of those experiments. For statistical significance of gener-
ated data, statistical comparisons between two means were determined
with Student’s t test. Although in a few figures studies from multiple groups
are presented, the statistical significance was tested by comparing data of
two groups, and significantly altered values (P ≤ 0.05) are highlighted in
figures by an asterisk. RNA-seq data were generated with n = 3 experi-
mental replicates per group. The statistical significance of altered gene ex-
pression (twofold change) was initially confirmed with right-tailed Fisher’s
exact test with P value cutoff set at 0.01. The final list of altered genes that
were presented in Fig. 5C was selected with an additional FDR cutoff set at
0.1. The raw data for RNA-seq analyses have been deposited and are avail-
able in the GEO database (accession no. GSE100285).
Additional details of experimental procedures are mentioned in
SI Appendix.
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